Diet Education Program for Stage I-IV Colorectal Cancer Survivors
NCT ID: NCT04597151
Last Updated: 2023-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2020-10-12
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial
NCT07087561
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
NCT00410579
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
NCT05746195
Testing Interventions to Motivate and Educate
NCT01568151
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
NCT04205955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To describe the feasibility and acceptability of a group diet education intervention for colorectal cancer (CRC) survivors at Zuckerberg San Francisco General Hospital (ZSFGH).
SECONDARY OBJECTIVE:
I. To describe perceived barriers to healthy diet among CRC survivors at ZSFGH.
EXPLORATORY OBJECTIVES:
I. To evaluate for differences in feasibility and acceptability of a group diet education program, based on sociodemographic factors such as education, food insecurity, employment, and race.
II. To explore changes in health-related behaviors pre and post intervention using a validated lifestyle score.
OUTLINE:
Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
After completion of study, patients are followed up at 12 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supportive care (diet education)
Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
Dietary Intervention
Attend diet education sessions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Intervention
Attend diet education sessions
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with stage 1- 4 colorectal cancer within 5 years prior to study enrollment and treated with curative intent
* Receiving survivorship follow up care at Zuckerberg San Francisco General Hospital (ZSFGH)
* Able to provide written consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sorbarikor Piawah, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zuckerberg San Francisco General Hospital
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2020-06808
Identifier Type: REGISTRY
Identifier Source: secondary_id
204511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.